Trial Profile
A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2015
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary)
- Indications Pemphigus vulgaris
- Focus Therapeutic Use
- Acronyms IMAT-PV
- Sponsors Biotest AG
- 16 Oct 2013 New trial record